| MSD Merck Sharp & Dohme AG - Gardasil 9, Injektionssuspension in Fertigspritze | | 65387 | | 01 | | Gardasil 9 | | Injektionssuspension in Fertigspritze | | J07BM03 | | Papillomavirus (Human Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | | 29.07.2016 | | |
| | Composition | | proteinum L1 papillomaviri humani typus 6 30 µg, proteinum L1 papillomaviri humani typus 11 40 µg, proteinum L1 papillomaviri humani typus 16 60 µg, proteinum L1 papillomaviri humani typus 18 40 µg, proteinum L1 papillomaviri humani typus 31 20 µg, proteinum L1 papillomaviri humani typus 33 20 µg, proteinum L1 papillomaviri humani typus 45 20 µg, proteinum L1 papillomaviri humani typus 52 20 µg, proteinum L1 papillomaviri humani typus 58 20 µg, aluminium ut aluminii hydroxyphosphas sulfas amorphus, natrii chloridum, histidinum, polysorbatum 80, natrii boras, aqua ad iniectabile ad suspensionem pro 0.5 ml corresp. natrium 3.78 mg. | | Packungsbestandteile | | Injektionssuspension in Fertigspritze | | | | | | Principe actif | Concentr. |
|---|
| Proteinum L1 Papillomaviri Humani Typus 11 | 40µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 16 | 60µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 18 | 40µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 31 | 20µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 33 | 20µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 45 | 20µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 52 | 20µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 58 | 20µg / 0.5ml | | Proteinum L1 Papillomaviri Humani Typus 6 | 30µg / 0.5ml |
| | | | Agents auxilliaires |
|---|
| Alumine | | Histidine | | Natrii Boras | | Sodium Chlorure | | Polysorbatum 80 |
|
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 001 | | DDP | DDP | B | | Oui | | 002 | 10 | DDP | DDP | B | | Oui |
|
|
